Kelly Gordon

Kelly Gordon, Ph.D., MB(ASCP)CM is VP, Companion Diagnostics at Acrivon Therapeutics, Inc. Kelly has worked in the oncology research field for over 20 years and the diagnostics industry for over 10 years developing innovative biomarker and diagnostic testing products.  She has experience working in both diagnostic and therapeutic companies driving the product development and regulatory strategy for high-value companion diagnostic assays, which include the multi-indication PD-L1 immunohistochemistry assays launched by Roche for the cancer immunotherapy TECENTRIQ and the pan-cancer genomics testing strategy for Loxo Oncology’s VITRAKVI.

Kelly received her B.S. in Molecular and Cellular Biology from the University of Arizona, Ph.D. in Pharmacology from Duke University, and completed her post-doctoral training in Cancer Biology at the Translational Genomics Research Institute and Arizona Cancer Center.